65 results
424B5
NBSE
NeuBase Therapeutics Inc
30 Jun 23
Prospectus supplement for primary offering
8:42am
to utilize its pre-change net operating losses (“NOLs”) to offset future taxable income (the “Section 382 Limitation”). Such an ownership change
10-QT
NBSE
NeuBase Therapeutics Inc
5 Jun 23
Quarterly report for transitional period
4:05pm
compensation expense, partially offset by depreciation and amortization expenses, and a decrease in prepaid insurance, other prepaid expenses and current … in accounts payable, partially offset by stock-based compensation expense, depreciation and amortization expenses, a decrease in prepaid expenses
424B5
m1fl mtffil
29 Dec 22
Prospectus supplement for primary offering
5:03pm
424B5
2q7oghclazep4vr yx
27 Aug 21
Prospectus supplement for primary offering
5:21pm
DEFA14A
chah8
2 Jul 21
Additional proxy soliciting materials
7:06am
424B5
hiut0xr28ha8a27spj0
23 Apr 21
Prospectus supplement for primary offering
4:05pm
424B5
i5ri y1zuinyeg
21 Apr 21
Prospectus supplement for primary offering
4:03pm